BALANCE Model & Medicare GLP-1 Coverage Explained

If you are on Medicare or Medicaid and have been priced out of GLP-1 medications like semaglutide or tirzepatide, two federal programs may change your situation significantly. The BALANCE Model and the Medicare GLP-1 Bridge are both designed to bring these treatments within reach for older and lower-income Americans.

Here is a clear breakdown of what each program involves, who may qualify, and what steps you can take right now.

What Is the BALANCE Model?

The BALANCE Model is a federal payment and delivery initiative developed by the Center for Medicare and Medicaid Innovation (CMMI), which sits within the Centers for Medicare and Medicaid Services (CMS). CMMI regularly tests new payment models to improve care quality and control costs. The BALANCE Model focuses specifically on anti-obesity medications (AOMs), including GLP-1 receptor agonists.

The core idea is to test whether covering GLP-1 medications for Medicare and Medicaid beneficiaries with obesity leads to better health outcomes and, over time, lower overall healthcare costs. Proponents argue that reducing obesity-related complications like heart disease, type 2 diabetes, and sleep apnea could offset the high price tag of these drugs.

The model is not a full federal mandate for coverage. Instead, it is a structured pilot program that would apply in selected states or health systems. Participating organizations agree to specific rules around prescribing, patient monitoring, and reporting. The goal is to generate data that could eventually inform a permanent, national coverage policy.

Why This Matters for Medicare Patients

Currently, Medicare Part D covers GLP-1 medications only when prescribed for type 2 diabetes, not for obesity alone. This gap has left millions of beneficiaries paying out of pocket for drugs like Wegovy (semaglutide) or Zepbound (tirzepatide), which can cost $900 to $1,300 per month without insurance.

The BALANCE Model would directly address this gap by allowing coverage for weight management indications, not just diabetes management.

What Is the Medicare GLP-1 Bridge?

The Medicare GLP-1 Bridge is a companion program designed to address a very practical problem: coverage changes take time to implement, but patients need access now.

The Bridge is intended to provide interim, subsidized access to GLP-1 medications for eligible Medicare beneficiaries while the broader BALANCE Model is being rolled out or evaluated. Think of it as a temporary on-ramp that prevents patients from falling through the gap during a policy transition.

Details about the Bridge program's specific mechanics, including which medications are covered, at what cost-sharing level, and through which Part D plans, are still being finalized based on federal guidance available through mid-2025. Patients and providers should check CMS updates regularly as implementation details emerge.

Key Difference Between the Two Programs

Which GLP-1 Medications Are Involved?

Both programs center on the newer generation of GLP-1 and dual GLP-1/GIP receptor agonists that have demonstrated clinically significant weight loss in large clinical trials.

The medications most likely to fall under these programs include:

• Semaglutide - sold as Wegovy for weight management and Ozempic for type 2 diabetes
• Tirzepatide - sold as Mounjaro for diabetes and Zepbound for weight management

Wegovy received FDA approval specifically for chronic weight management in adults with a BMI of 30 or higher, or 27 or higher with at least one weight-related condition. Zepbound carries similar labeling. These approvals are what make these drugs eligible for obesity-specific coverage considerations under these new programs.

Older GLP-1 medications like liraglutide (Saxenda, Victoza) may also be relevant, but the primary policy focus is on the higher-efficacy, once-weekly injectable options.

Who Might Qualify?

Eligibility details are still being refined, but based on the structure of the BALANCE Model and existing CMS frameworks, the following criteria are likely to be relevant:

Medicare Eligibility Factors

• Enrollment in Medicare Part D prescription drug coverage
• BMI of 30 or higher meeting the clinical threshold for obesity, or BMI of 27 or higher with a qualifying weight-related condition such as hypertension, cardiovascular disease, or type 2 diabetes
• No active contraindication to GLP-1 therapy, including personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2
• Participation through a provider or health system that is enrolled in the BALANCE Model pilot program, since coverage applies within participating organizations rather than universally across all Medicare plans

Medicaid Eligibility Factors

Medicaid coverage of GLP-1s varies significantly by state, since states administer Medicaid programs with federal guidance but considerable autonomy. The BALANCE Model may create incentives or requirements for participating states to expand their Medicaid formularies to include GLP-1s for obesity, not just diabetes.

If you are on Medicaid and currently paying out of pocket for a GLP-1, it is worth asking your state Medicaid office whether your state is participating in the BALANCE Model or has independently expanded GLP-1 coverage.

What the Cost Picture Looks Like

The financial stakes here are enormous. GLP-1 medications are among the most expensive drugs on the market, and Medicare Part D beneficiaries have historically had no coverage pathway for obesity-specific prescriptions.

Under standard Part D cost-sharing, even with coverage, patients could still owe a significant copay or coinsurance amount. The BALANCE Model and Bridge programs are intended to reduce this burden, though the exact cost-sharing structure for participants has not been fully published as of this writing.

One important development worth noting: the Inflation Reduction Act of 2022 introduced a $2,000 annual out-of-pocket cap for Part D enrollees starting in 2025. This cap could meaningfully limit total annual spending for Medicare patients who gain access to GLP-1 coverage under these programs.

If you are looking for savings options available right now while waiting for these programs to roll out, check the GLP-1 Coupons page for manufacturer savings cards and pharmacy discounts that may apply regardless of your insurance status.

The Broader Policy Context

These programs do not exist in a vacuum. They reflect years of advocacy from obesity medicine specialists, patient groups, and health economists who have argued that obesity should be treated as a chronic disease, not a lifestyle choice, and that the medications to treat it should be covered accordingly.

The Treat and Reduce Obesity Act (TROA) is federal legislation that has been introduced multiple times in Congress with the goal of requiring Medicare to cover obesity counseling and pharmacotherapy, including GLP-1s. While TROA has not yet passed, it has shaped the policy environment that produced the BALANCE Model.

At the same time, CMS and the Congressional Budget Office have grappled seriously with the budget implications. Covering GLP-1s for the estimated 3.6 million Medicare beneficiaries who might qualify could cost tens of billions of dollars annually at current drug prices. The BALANCE Model is partly a way to gather data on whether the long-term health savings justify that upfront investment.

This context matters for patients because it signals that coverage expansion is moving in a clear direction, but the pace and scope may be shaped by budget negotiations and political factors outside of CMS control.

What to Ask Your Doctor Right Now

You do not need to wait for these programs to be fully operational to take action. There are concrete steps you can take today.

Questions to Bring to Your Next Appointment

1. Is my BMI and medical history documented in a way that would support a GLP-1 prescription for obesity, not just for diabetes?

2. Are you or your practice enrolled in any CMMI pilot programs, including the BALANCE Model?

3. What diagnosis codes are you using when prescribing, and do they support coverage under my Part D plan?

4. Have you filed a prior authorization for a GLP-1 for weight management under my Medicare plan, and what was the result?

5. Are there any bridge program applications I should be aware of through my Part D insurer?

Documenting comorbidities like hypertension, cardiovascular disease, sleep apnea, or pre-diabetes alongside an obesity diagnosis strengthens any coverage request significantly.

If you are not yet connected with a provider who specializes in GLP-1 prescribing and insurance navigation, the Best Providers comparison page lists telehealth and in-person options with experience handling complex coverage situations.